APO RESEARCH · REPORT
Bendamustine
Bendamustine is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein.
Product & engineering
Understand the product.
Bendamustine is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein.
Selected research
Industry Research
Bendamustine Industry Research Report 2026
Market perspective
Bendamustine is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein.
Market competition is intense. Teva, Eisai, Eagle Pharmaceuticals, MundiPharma, Mylan, Natco Pharma, Emcure, etc. are the leaders of the industry, with Teva occupies the major markets share of over 83% in 2018.
Report Scope
Read the full market overview
This report quantifies the global Bendamustine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bendamustine Market by Company
Teva
Eisai
Eagle Pharmaceuticals
MundiPharma
Mylan
Natco Pharma
Emcure
Miracalus Pharma
Bendamustine Segment by Type
25mg Injection
100mg Injection
Others
Bendamustine Segment by Application
Chronic Lymphocytic Leukemia
Multiple Myeloma
Non-Hodgkin's Lymphoma
Bendamustine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bendamustine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bendamustine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bendamustine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bendamustine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bendamustine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bendamustine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 25mg Injection
- 100mg Injection
- Others
Applications
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
Companies covered
- Teva
- Eisai
- Eagle Pharmaceuticals
- MundiPharma
- Mylan
- Natco Pharma
- Emcure
- Miracalus Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Bendamustine Market Size (2021-2032)
- 2.2.2 Global Bendamustine Sales (2021-2032)
- 2.2.3 Global Bendamustine Market Average Price (2021-2032)
- 2.3 Bendamustine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 25mg Injection
- 2.3.3 100mg Injection
- 2.3.4 Others
- 2.4 Bendamustine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Chronic Lymphocytic Leukemia
- 2.4.3 Multiple Myeloma
- 2.4.4 Non-Hodgkin's Lymphoma
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Bendamustine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Bendamustine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Bendamustine Revenue of Manufacturers (2021-2026)
- 3.4 Global Bendamustine Average Price by Manufacturers (2021-2026)
- 3.5 Global Bendamustine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Bendamustine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Bendamustine, Product Type & Application
- 3.8 Global Manufacturers of Bendamustine, Established Date
- 3.9 Global Bendamustine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Bendamustine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Bendamustine Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Eisai
- 4.2.1 Eisai Company Information
- 4.2.2 Eisai Business Overview
- 4.2.3 Eisai Bendamustine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eisai Bendamustine Product Portfolio
- 4.2.5 Eisai Recent Developments
- 4.3 Eagle Pharmaceuticals
- 4.3.1 Eagle Pharmaceuticals Company Information
- 4.3.2 Eagle Pharmaceuticals Business Overview
- 4.3.3 Eagle Pharmaceuticals Bendamustine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eagle Pharmaceuticals Bendamustine Product Portfolio
- 4.3.5 Eagle Pharmaceuticals Recent Developments
- 4.4 MundiPharma
- 4.4.1 MundiPharma Company Information
- 4.4.2 MundiPharma Business Overview
- 4.4.3 MundiPharma Bendamustine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 MundiPharma Bendamustine Product Portfolio
- 4.4.5 MundiPharma Recent Developments
- 4.5 Mylan
- 4.5.1 Mylan Company Information
- 4.5.2 Mylan Business Overview
- 4.5.3 Mylan Bendamustine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mylan Bendamustine Product Portfolio
- 4.5.5 Mylan Recent Developments
- 4.6 Natco Pharma
- 4.6.1 Natco Pharma Company Information
- 4.6.2 Natco Pharma Business Overview
- 4.6.3 Natco Pharma Bendamustine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Natco Pharma Bendamustine Product Portfolio
- 4.6.5 Natco Pharma Recent Developments
- 4.7 Emcure
- 4.7.1 Emcure Company Information
- 4.7.2 Emcure Business Overview
- 4.7.3 Emcure Bendamustine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Emcure Bendamustine Product Portfolio
- 4.7.5 Emcure Recent Developments
- 4.8 Miracalus Pharma
- 4.8.1 Miracalus Pharma Company Information
- 4.8.2 Miracalus Pharma Business Overview
- 4.8.3 Miracalus Pharma Bendamustine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Miracalus Pharma Bendamustine Product Portfolio
- 4.8.5 Miracalus Pharma Recent Developments
5 Global Bendamustine Market Scenario by Region
- 5.1 Global Bendamustine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Bendamustine Sales by Region: 2021-2032
- 5.2.1 Global Bendamustine Sales by Region: 2021-2026
- 5.2.2 Global Bendamustine Sales by Region: 2027-2032
- 5.3 Global Bendamustine Revenue by Region: 2021-2032
- 5.3.1 Global Bendamustine Revenue by Region: 2021-2026
- 5.3.2 Global Bendamustine Revenue by Region: 2027-2032
- 5.4 North America Bendamustine Market Facts & Figures by Country
- 5.4.1 North America Bendamustine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Bendamustine Sales by Country (2021-2032)
- 5.4.3 North America Bendamustine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Bendamustine Market Facts & Figures by Country
- 5.5.1 Europe Bendamustine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Bendamustine Sales by Country (2021-2032)
- 5.5.3 Europe Bendamustine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Bendamustine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Bendamustine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Bendamustine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Bendamustine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Bendamustine Market Facts & Figures by Country
- 5.7.1 South America Bendamustine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Bendamustine Sales by Country (2021-2032)
- 5.7.3 South America Bendamustine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Bendamustine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Bendamustine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Bendamustine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Bendamustine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Bendamustine Sales by Type (2021-2032)
- 6.1.1 Global Bendamustine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Bendamustine Sales Market Share by Type (2021-2032)
- 6.2 Global Bendamustine Revenue by Type (2021-2032)
- 6.2.1 Global Bendamustine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Bendamustine Revenue Market Share by Type (2021-2032)
- 6.3 Global Bendamustine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Bendamustine Sales by Application (2021-2032)
- 7.1.1 Global Bendamustine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Bendamustine Sales Market Share by Application (2021-2032)
- 7.2 Global Bendamustine Revenue by Application (2021-2032)
- 7.2.1 Global Bendamustine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Bendamustine Revenue Market Share by Application (2021-2032)
- 7.3 Global Bendamustine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Bendamustine Value Chain Analysis
- 8.1.1 Bendamustine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Bendamustine Production Mode & Process
- 8.2 Bendamustine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Bendamustine Distributors
- 8.2.3 Bendamustine Customers
9 Global Bendamustine Analyzing Market Dynamics
- 9.1 Bendamustine Industry Trends
- 9.2 Bendamustine Industry Drivers
- 9.3 Bendamustine Industry Opportunities and Challenges
- 9.4 Bendamustine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst